Tord is the Chairman of the Board of SciBase and has been a member of the board since 2014. Tord has extensive experience as a CEO in different MedTech companies and from Board assignments in both Swedish and international listed companies and owner-managed companies. Among other things, Tord has been the CEO of Synectics Medical Inc, Synectics Medical AB, Dantec AS, Artimplant AB, VP of Medtronic and Division Manager for Sandvik MedTech. Tord has an upper-secondary education in engineering and unfinished studies in industrial engineering from the Linköping University (1980-1984). In addition to his board work. Tord Lendau has been on multiple boards in the US, Holland, South Africa Korea etc and has amongst other also served as a Mentor and Speaker in Rapid Growth, Change and Talent Management for Executive Management Courses for the last 15 years.

Current assignments:
Tord is currently Chairman of the Boards of Actea Consulting AB, Encare AB, Hubbster AB, Promimic AB, Embedded Nanotech AB and Lendau Capital AB. Tord is also Boardmember and chairman of the audit committee at Vitrolife AB (publ) and member of the jury for the Nanotech Company of the Year at Sweden Nanotech/IVA.

Per Aniansson is an Investment Director at Fouriertransform AB and has been a member of the Board since 2014. He holds an MSc Engineering Physics from Chalmers University of Technology and an MBA from INSEAD. Mr Aniansson has 20 years of experience in life science and investments ranging from start-ups to large public companies. He has previously held positions at Industrivärden, Siemens and Innovationskapital. Mr Aniansson has six years of experience as management consultant at Accenture and Arthur D Little, mainly with a focus in the Pharma and Medtech business. He also has entrepreneurial experience as a CEO in two UK based medtech companies, one within medical devices (Syringes) and one within IVD and devices targeting the colorectal cancer diagnostics market.

Current assignments:
Investment director at Fouriertransform Aktiebolag. Member of the Boards of Ossdsign AB, Origin Sciences Ltd., Star Syringe Ltd., Stiftelsen Bota Cancer, ÅAC Microtec AB, Renewcell AB and Anian AB.

Renee has been a member of the board since 2014. Renee holds a BA in Finance from the Stockholm School of Economics and an MBA from INSEAD. Renee was previously a partner at Omega Funds Management UK L.L.P. in London and 3i Group Plc with a focus on investments in healthcare and life sciences. She previously worked at investment banks in the U.S. and Europe with a focus on acquisitions, divestments and financing of growth companies. Renee has extensive experience of board work in owner-managed, public and international companies. Renee holds a BA in Finance from the Stockholm School of Economics and an MBA from INSEAD.

Current assignments:
Managing partner at Positive Capital Partners and Chairman of the Boards of Simparel Inc and EnXray Ltd.

Diana joined the Board in 2017. Diana holds an MBA from the University of Berlin and various follow-on educations among them an exam in medical marketing from UCLA (the University of California Los Angeles). Diana is today the CEO of Medskin Solutions Dr Suwelack AG with over 130 employees in Europe, the US and Japan. She has an extensive experience from various senior positions within the Pharmaceutical industry in both the US and Europe.

Current assignments:
CEO at Medskin Solutions Dr Suwelack AG.

Thomas holds an MBA from the Stockholm School of Economics and joined the Board in 2017. He is an independent advisor, investor and board member within the Health Care industry. Thomas has extensive experience from senior positions such as CEO & Head of Investor Growth Capital. He has also been Investment Director in Alfred Berg ABN AMRO Capital Investment AB and Vice President in Handelsbanken Markets.

Current assignments:
Chairman of the Board of Moberg Pharma AB, Itrim AB and Sedana Medical AB. Member of the Board of Boule Diagnostics AB, Biotage AB, Memira AB and Swedencare AB

Thomas joined the Board in 2017. Thomas holds a Ph. D. in organic chemistry form the Technical University of Berlin and has also studied Economics, chemistry and physics at the University of Göttingen. He is today the CFO of Medigene AG. Thomas has an extensive experience from senior positions within the Pharmaceutical industry such as CEO/CFO of Epigenomics AG where he led the company’s efforts in gaining regulatory approval for the first blood-based molecular diagnostic cancer screening test by the FDA and oversaw its subsequent introduction into the US market. Before that he worked at Sanofi and various VC-Companies in both Germany as well as the US.

Current assignments:
CFO at Medigene AG and member of the board at Immunic AG.

Independence
Thomas is independent in relation to the Company and the Company’s management and to the Company’s major shareholders.